Latest BioLineRx News & Updates

See the latest news and media coverage for BioLineRx. We track all announcements, press releases, and industry mentions in real time, all in one place.

BioLineRx

Biopharmaceutical company focused on oncology and rare diseases

biolinerx.com

Headquarters: Modi'in, Israel
Founded year: 2003
Company type: Public company
Number of employees: 40–50
Industry: Pharmaceuticals

Last updated Today

Latest news about BioLineRx

In short: BioLineRx initiated GLIX1 trials for glioblastoma and reported preclinical synergy in ovarian cancer while securing its cash runway.

Company announcements

July 20 BioLineRx

BioLineRx and Hemispherian to present synergy data at ESMO 2026

Abstract showing GLIX1 synergy with PARP inhibitors in ovarian cancer cells accepted as e-Poster at ESMO 2026.

May 28 BioLineRx

BioLineRx reports Q1 2026 financial results and corporate update

First patient dosed in Phase 1/2a GLIX1 trial; new preclinical data showed tumor inhibition; cash runway into H1 2027.

May 20 BioLineRx

BioLineRx to report first quarter 2026 results on May 27

Management will hold a conference call at 8:30 a.m. EDT. The release will be before U.S. markets open.

April 28 BioLineRx

BioLineRx and Hemispherian dose first patient in GLIX1 study

The Phase 1/2a trial is for recurrent glioblastoma, with data expected in H1 2027.

Media coverage

August 28 Financial Times

BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement

Chardan is acting as the exclusive placement agent for the offering. The aggregate gross proceeds to the Company from the offering are expected to be...

August 19 The Globe and Mail

BioLineRx Sets September 23, 2026 Shareholders Meeting to Boost Capital and Approve New Equity Awards

Detailed price information for Biolinerx Ltd ADR (BLRX-Q) from The Globe and Mail including charting and trades.

July 9 Stockhouse

BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide

TEL AVIV, Israel, Oct. 16, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases...

July 8 Yahoo Finance

BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft ...

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company...

Never miss news about BioLineRx

Track BioLineRx and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

BioLineRx competitors & trending companies

Browse news for competitors to BioLineRx and other trending companies.